Plain-English translation of NCT06966427 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a dosing guidance system (DGS)—a smart tool that reads your continuous glucose monitor and helps recommend how much insulin you should take. The system will be tested in people with type 1 or type 2 diabetes who are either starting basal insulin or already taking multiple daily insulin injections. Researchers want to make sure the system is safe and helpful for managing your blood sugar.
Many people with diabetes struggle to figure out the right insulin dose at the right time, which can lead to blood sugar levels that are too high or too low. This new treatment aims to give people personalized, real-time guidance so they can make better insulin decisions on their own.
You likely qualify if…
You likely don't qualify if…
You will be in the study for about 8–10 weeks total: a 2–4 week run-in period where you get used to the glucose monitor, followed by a 6-week main study. During the main phase, you'll use the smart dosing guidance system whenever you take insulin—it will help recommend doses based on your glucose readings and what you log. You'll need to wear the continuous glucose monitor, manually record each insulin dose and meal on your smartphone, and track your daily activities. The study will compare two slightly different versions of the system to see which works best and is safest.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Israel
Slovenia